|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MTERF1 |
Gene summary for MTERF1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MTERF1 | Gene ID | 7978 |
| Gene name | mitochondrial transcription termination factor 1 | |
| Gene Alias | MTERF | |
| Cytomap | 7q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0000959 | UniProtAcc | B4DPR9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7978 | MTERF1 | PTC04 | Human | Thyroid | PTC | 3.25e-04 | 6.23e-02 | 0.1927 |
| 7978 | MTERF1 | PTC05 | Human | Thyroid | PTC | 1.37e-03 | 1.71e-01 | 0.2065 |
| 7978 | MTERF1 | PTC06 | Human | Thyroid | PTC | 2.20e-04 | 1.22e-01 | 0.2057 |
| 7978 | MTERF1 | PTC07 | Human | Thyroid | PTC | 1.95e-11 | 1.04e-01 | 0.2044 |
| 7978 | MTERF1 | ATC12 | Human | Thyroid | ATC | 1.02e-04 | 7.08e-02 | 0.34 |
| 7978 | MTERF1 | ATC13 | Human | Thyroid | ATC | 9.70e-38 | 6.49e-01 | 0.34 |
| 7978 | MTERF1 | ATC2 | Human | Thyroid | ATC | 4.57e-08 | 5.00e-01 | 0.34 |
| 7978 | MTERF1 | ATC4 | Human | Thyroid | ATC | 4.79e-03 | 9.24e-02 | 0.34 |
| 7978 | MTERF1 | ATC5 | Human | Thyroid | ATC | 7.72e-40 | 7.06e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:01400536 | Thyroid | PTC | mitochondrial gene expression | 51/5968 | 108/18723 | 6.04e-04 | 3.83e-03 | 51 |
| GO:00323928 | Thyroid | PTC | DNA geometric change | 41/5968 | 90/18723 | 4.47e-03 | 2.11e-02 | 41 |
| GO:014005314 | Thyroid | ATC | mitochondrial gene expression | 51/6293 | 108/18723 | 2.26e-03 | 1.06e-02 | 51 |
| GO:003239216 | Thyroid | ATC | DNA geometric change | 42/6293 | 90/18723 | 6.81e-03 | 2.70e-02 | 42 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| MTERF1 | BN | Thyroid | ATC | BEST1,CD160,CEP250, etc. | 3.14e-02 |  |
| MTERF1 | TH2 | Thyroid | goiters | BEST1,CD160,CEP250, etc. | 1.33e-02 |  |
| MTERF1 | CD8TEXINT | Thyroid | Healthy | BEST1,CD160,CEP250, etc. | 1.37e-02 |  |
| MTERF1 | GDT | Thyroid | Healthy | BEST1,CD160,CEP250, etc. | 1.38e-02 | |
| MTERF1 | GC | Thyroid | Healthy | BEST1,CD160,CEP250, etc. | 1.41e-02 | |
| MTERF1 | pDC | Thyroid | HT | BEST1,CD160,CEP250, etc. | 0.00e+00 |  |
| MTERF1 | TFH | Thyroid | HT | BEST1,CD160,CEP250, etc. | 0.00e+00 | |
| MTERF1 | M2MAC | Thyroid | HT | BEST1,CD160,CEP250, etc. | 0.00e+00 | |
| MTERF1 | TFH | Thyroid | PTC | BEST1,CD160,CEP250, etc. | 9.73e-03 |  |
| MTERF1 | TH1 | Thyroid | PTC | BEST1,CD160,CEP250, etc. | 5.14e-03 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MTERF1 | SNV | Missense_Mutation | c.675G>C | p.Leu225Phe | p.L225F | Q99551 | protein_coding | deleterious(0.03) | benign(0.391) | TCGA-BH-A0BF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MTERF1 | SNV | Missense_Mutation | novel | c.493G>A | p.Glu165Lys | p.E165K | Q99551 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| MTERF1 | SNV | Missense_Mutation | rs374588825 | c.400C>T | p.Arg134Cys | p.R134C | Q99551 | protein_coding | tolerated(0.16) | possibly_damaging(0.842) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MTERF1 | SNV | Missense_Mutation | rs150415937 | c.89G>T | p.Arg30Ile | p.R30I | Q99551 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.986) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MTERF1 | SNV | Missense_Mutation | novel | c.1109N>A | p.Gly370Asp | p.G370D | Q99551 | protein_coding | tolerated(0.09) | possibly_damaging(0.487) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MTERF1 | SNV | Missense_Mutation | rs190837494 | c.128G>A | p.Arg43Gln | p.R43Q | Q99551 | protein_coding | tolerated(0.76) | benign(0) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| MTERF1 | SNV | Missense_Mutation | novel | c.5A>C | p.Gln2Pro | p.Q2P | Q99551 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.483) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| MTERF1 | SNV | Missense_Mutation | rs777960484 | c.1085N>A | p.Arg362Gln | p.R362Q | Q99551 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| MTERF1 | SNV | Missense_Mutation | novel | c.987N>A | p.Asn329Lys | p.N329K | Q99551 | protein_coding | tolerated(0.2) | probably_damaging(0.969) | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MTERF1 | SNV | Missense_Mutation | rs777960484 | c.1085N>A | p.Arg362Gln | p.R362Q | Q99551 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |